Moniati Foteini, Vassiliou Marianna, Costa Christos, Chatzimatthaiou Constantina, Chatzimatthaiou Marios
Faculty of Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Faculty of Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Dermatol Res Pract. 2025 Aug 20;2025:8867838. doi: 10.1155/drp/8867838. eCollection 2025.
Primary palmar hyperhidrosis (PH) is a chronic condition characterized by excessive sweating in the palms, significantly affecting the quality of life (QOL) of affected individuals. Despite the availability of various treatment modalities, the long-term efficacy and safety of these interventions remain unclear, warranting a comprehensive evaluation. This systematic review aims to assess the efficacy, safety and patient-reported outcomes of treatments for PH. A systematic search was conducted in PubMed, Embase and the Cochrane Library from their inception until March 2024, adhering to PRISMA guidelines. Inclusion criteria focused on prospective and retrospective studies examining PH treatments published in English. Data from eligible studies were extracted, analysed qualitatively and reported based on outcomes, including efficacy, QOL improvements and adverse effects. Fourteen studies, including 1733 patients aged 4-77 years, were included in the final review. The treatments assessed included oral and topical oxybutynin, iontophoresis, botulinum toxin A injections, photodynamic therapy (PDT) and endoscopic thoracic sympathectomy (ETS). Oral oxybutynin demonstrated symptomatic relief in 60%-97% of the patients although anticholinergic side effects were frequently reported. ETS, while providing the highest rates of complete sweat cessation, was associated with compensatory hyperhidrosis. Noninvasive treatments like iontophoresis showed moderate efficacy with minimal side effects but required ongoing sessions for maintenance. This review highlights the efficacy of several therapeutic approaches for PH though most treatments are hindered by significant adverse effects or practical limitations. Future research should prioritize long-term studies and standardized outcome measures to guide clinical decision-making more effectively.
原发性手掌多汗症(PH)是一种慢性疾病,其特征为手掌过度出汗,严重影响患者的生活质量(QOL)。尽管有多种治疗方式可供选择,但这些干预措施的长期疗效和安全性仍不明确,因此需要进行全面评估。本系统评价旨在评估PH治疗的疗效、安全性及患者报告的结局。从创刊至2024年3月,我们按照PRISMA指南在PubMed、Embase和Cochrane图书馆进行了系统检索。纳入标准聚焦于以英文发表的、研究PH治疗的前瞻性和回顾性研究。提取符合条件的研究数据,进行定性分析,并根据疗效、生活质量改善情况和不良反应等结局进行报告。最终综述纳入了14项研究,共1733例年龄在4至77岁之间的患者。评估的治疗方法包括口服和外用奥昔布宁、离子电渗疗法、肉毒杆菌毒素A注射、光动力疗法(PDT)和内镜胸交感神经切除术(ETS)。口服奥昔布宁使60%-97%的患者症状缓解,不过抗胆碱能副作用报告频繁。ETS虽然完全停止出汗的比例最高,但与代偿性多汗症相关。离子电渗疗法等非侵入性治疗显示出中等疗效,副作用最小,但需要持续治疗以维持效果。本综述强调了几种治疗PH方法的疗效,不过大多数治疗受到显著不良反应或实际限制的阻碍。未来研究应优先开展长期研究并采用标准化结局指标,以更有效地指导临床决策。